ArticleNature2025
Mitochondrial metabolism sustains DNMT3A-R882-mutant clonal haematopoiesis.
Abstract read
In one paragraph
Article in Nature, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed.
- Mechanisms of Hematopoietic Stem Cell Aging and Emerging Rejuvenation Strategies.Stem cell reviews and reports · 2026Review
- Extracellular vesicles from aged individuals trigger mitochondrial dysfunction in hematopoietic progenitor cells.Haematologica · 2026Article
- Oncogenic DHX15 mutation enhances mitochondrial metabolism and sustains leukemia stemness.Leukemia · 2026Article
- Modern Concepts in Precision Targeting of Acute Myeloid Leukemia Based on Principles of Molecular Oncology.Cancers · 2026Review
- Statin Use and Genetically Predicted HMG-CoA Reductase Inhibition in Relation to Clonal Hematopoiesis.medRxiv : the preprint server for health sciences · 2026Article
- Clonal Hematopoiesis and Type 2 Diabetes: A Narrative Review.Journal of diabetes · 2026Review
- Deciphering the Anti-Tumor Mechanisms of Metformin Through Reprogramming of the Tumor Microenvironment.Cells · 2026Review
- MO-IPS suppresses acute myeloid leukemia through metabolic reprogramming and synergizes with anti-PD-1 immunotherapy.Functional & integrative genomics · 2026Article
- Current Understanding of CHIP's Immunobiological Footprint with A Focus on Gastrointestinal Disorders: A Review of the Literature.Current oncology reports · 2026Review
- Ligature-induced periodontitis promotesHaematologica · 2026Article
- Metabolic Crosstalk Between Host and Tumor as a Circuit of Resilience in Cancer Therapy.Cells · 2026Review
- Clonal haematopoiesis and cardiovascular disease, defining risk, filling gaps, and framing the future.NPJ cardiovascular health · 2026Review
- CHIP clinics: a practical overview of structure and function.Blood cancer journal · 2026Review
- Inflammageing and clonal haematopoiesis interplay and their impact on human disease.Nature reviews. Molecular cell biology · 2026Review
- Clinical decisions in clonal hematopoiesis: a contemporary review for clinicians.Haematologica · 2026Review
- Novel and emerging therapeutic strategies for clonal hematopoiesis.Haematologica · 2026Review
- Clonal hematopoiesis and its progression to myeloid neoplasms: insights into risk, biology, and therapeutic strategies.Haematologica · 2026Review
- Clonal Hematopoiesis in HIV and Atherosclerosis, Arterial Inflammation, and Lymph Node Metabolic Activity.medRxiv : the preprint server for health sciences · 2026Article
- Polθ activity modulates sensitivity to standard therapies in DNMT3A-deficient leukemia.Cell reports. Medicine · 2026Article
- Intrinsic and niche-dependent metabolic regulation of haematopoietic stem cells and implications for leukaemogenesis.Nature cell biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
42 authors.
Malgorzata GozdeckaCambridge Stem Cell Institute, University of Cambridge, Cambridge, UK. mg717@cam.ac.uk.ORCID 0000-0002-3134-1276
Monika Dudek *Cambridge Stem Cell Institute, University of Cambridge, Cambridge, UK.
Sean Wen *Department of Haematology, University of Cambridge, Cambridge, UK.
Muxin GuCambridge Stem Cell Institute, University of Cambridge, Cambridge, UK.
Richard J StopforthCambridge Institute of Therapeutic Immunology and Infectious Disease (CITIID), Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge, UK.ORCID 0000-0002-0054-7503
Justyna RakCambridge Stem Cell Institute, University of Cambridge, Cambridge, UK.
Aristi DamaskouCambridge Stem Cell Institute, University of Cambridge, Cambridge, UK.
Guinevere L GriceCambridge Institute of Therapeutic Immunology and Infectious Disease (CITIID), Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge, UK.
Matthew A McLoughlinCambridge Stem Cell Institute, University of Cambridge, Cambridge, UK.ORCID 0000-0002-4782-5718
Laura BondCambridge Stem Cell Institute, University of Cambridge, Cambridge, UK.ORCID 0000-0001-6115-655X
Rachael WilsonCambridge Stem Cell Institute, University of Cambridge, Cambridge, UK.ORCID 0000-0001-5129-7295
George GiotopoulosCambridge Stem Cell Institute, University of Cambridge, Cambridge, UK.ORCID 0000-0003-1390-6592
Vijaya Mahalingam ShanmugiahCambridge Stem Cell Institute, University of Cambridge, Cambridge, UK.
Rula Bany BakarCambridge Institute of Therapeutic Immunology and Infectious Disease (CITIID), Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge, UK.ORCID 0000-0002-5643-0195
Eliza YankovaCambridge Stem Cell Institute, University of Cambridge, Cambridge, UK.ORCID 0000-0003-2913-0012
Jonathan L CooperCambridge Stem Cell Institute, University of Cambridge, Cambridge, UK.
Nisha NarayanCambridge Stem Cell Institute, University of Cambridge, Cambridge, UK.ORCID 0000-0002-4106-2166
Sarah J HortonCambridge Stem Cell Institute, University of Cambridge, Cambridge, UK.ORCID 0000-0001-8418-5783
Ryan AsbyCambridge Stem Cell Institute, University of Cambridge, Cambridge, UK.
Dean C PaskCambridge Stem Cell Institute, University of Cambridge, Cambridge, UK.
Annalisa MupoAltos Labs, Granta Park, Cambridge, UK.
Graham DuddyThe Francis Crick Institute, London, UK.
Ludovica MarandoCambridge Stem Cell Institute, University of Cambridge, Cambridge, UK.
Theodoros GeorgomanolisCluster of Excellence Cellular Stress Responses in Aging-associated Diseases (CECAD), University Hospital Cologne, Cologne, Germany.
Paul CarterSection of Cardiovascular Medicine, The Victor Phillip Dahdalleh Heart and Lung Research Institute, The University of Cambridge, Papworth Road, Cambridge Biomedical Campus, Cambridge, UK.
Amirtha Priya RameshCambridge Stem Cell Institute, University of Cambridge, Cambridge, UK.
William G DunnCambridge Stem Cell Institute, University of Cambridge, Cambridge, UK.
Clea BarcenaCambridge Stem Cell Institute, University of Cambridge, Cambridge, UK.ORCID 0000-0002-7452-2536
Paolo GallipoliCentre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK.ORCID 0000-0001-7254-2253
Kosuke YusaStem Cell Genetics, Institute for Life and Medical Sciences, Kyoto University, Kyoto, Japan.
Slavé PetrovskiCentre for Genomics Research, Discovery Sciences, BioPharmaceuticals Research and Development, AstraZeneca, Cambridge, UK.
Penny WrightDepartment of Anatomic Pathology, Canterbury Health Laboratories, Christchurch, New Zealand.
Pedro M QuirosCambridge Stem Cell Institute, University of Cambridge, Cambridge, UK.ORCID 0000-0002-7793-6291
Christian FrezzaCluster of Excellence Cellular Stress Responses in Aging-associated Diseases (CECAD), University Hospital Cologne, Cologne, Germany.ORCID 0000-0002-3293-7397
James A NathanCambridge Institute of Therapeutic Immunology and Infectious Disease (CITIID), Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge, UK.ORCID 0000-0002-0248-1632
Arthur KaserCambridge Institute of Therapeutic Immunology and Infectious Disease (CITIID), Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge, UK.ORCID 0000-0003-1419-3344
Siddhartha KarEarly Cancer Institute, Department of Oncology, University of Cambridge, Cambridge, UK.
Konstantinos TzelepisCambridge Stem Cell Institute, University of Cambridge, Cambridge, UK.ORCID 0000-0002-4865-7648
Jonathan MitchellCentre for Genomics Research, Discovery Sciences, BioPharmaceuticals Research and Development, AstraZeneca, Cambridge, UK.ORCID 0000-0003-3792-4058
Margarete A FabreDepartment of Haematology, University of Cambridge, Cambridge, UK.ORCID 0000-0001-7794-610X
Brian J P HuntlyCambridge Stem Cell Institute, University of Cambridge, Cambridge, UK. bjph2@cam.ac.uk.ORCID 0000-0003-0312-161X
George S VassiliouCambridge Stem Cell Institute, University of Cambridge, Cambridge, UK. gsv20@cam.ac.uk.ORCID 0000-0003-4337-8022
Funding
Wellcome Trust
Abstract
Somatic DNMT3A-R882 codon mutations drive the most common form of clonal haematopoiesis (CH) and are associated with increased acute myeloid leukaemia (AML) risk
Indexed as
Clonal HematopoiesisDNA (Cytosine-5-)-MethyltransferasesMitochondriaMutationAnimalsClone CellsDNA Methyltransferase 3AElectron Transport Complex IFemaleHematopoietic Stem CellsHumansLeukemia, Myeloid, AcuteMaleMetforminMiceOxidative PhosphorylationDNA (Cytosine-5-)-MethyltransferasesDNA Methyltransferase 3ADNMT3A protein, humanDnmt3a protein, mouseElectron Transport Complex IMetformin
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.